Toripalimab with standard treatment for HPV-positive throat cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study tests adding a new immunotherapy drug (toripalimab) to standard chemo for HPV-positive throat cancer. It aims to see if this combination works better than chemo alone for patients whose cancer has spread to nodes but not to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have throat cancer caused by HPV type 16 (a specific virus).
- The cancer must have spread to lymph nodes in the neck or be a larger tumor, but not spread to distant organs.
- You cannot have had chemotherapy or radiation for head and neck cancer before.
- You must be healthy enough to get a standard chemo drug called cisplatin.
- You must be 18 or older and able to follow daily activities without major limitations.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
This trial tests a special type of immune cell therapy for advanced throat cancer tied to HPV infection. Your own immune cells are reprogrammed in a lab to better attack cancer cells, then given back to you. It aims to help people whose cancer has not responded to standard treatments.
This study tests whether adding an immunotherapy drug (toripalimab) to chemotherapy before surgery can help shrink tumors and improve outcomes for patients with locally advanced head and neck cancer. It aims to see if this combination is better than surgery alone or surgery with chemotherapy.
This trial tests a new nasal vaccine combined with an immunotherapy drug (tislelizumab) given before surgery for people with HPV-positive oropharyngeal cancer. The goal is to help the immune system fight the cancer and potentially improve outcomes after surgery.
This trial tests whether continuing treatment with an immunotherapy drug called toripalimab after standard treatment helps prevent head and neck cancer from coming back. It's for patients with high-risk features who have no remaining cancer after their first treatment.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
Hear when a new Oropharyngeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.